SuperworthNU Skin Enterprises revenue NUS
Sales by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- $1.4B
- Latest quarter, Q2 FY26
- $320.1M
- −17% on a year earlier
- Fiscal year 2025
- $1.5B
- −14% on the year before
NU Skin Enterprises' revenue was $1.4B over the twelve months to Jun 30, 2026, down 15% on a year earlier.
In its latest quarter, Q2 FY26, it was $320.1M, down 17% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 10% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $1.5B | −14% |
| FY2024 | $1.7B | −12% |
| FY2023 | $2B | −12% |
| FY2022 | $2.2B | −17% |
| FY2021 | $2.7B | +4% |
| FY2020 | $2.6B | +7% |
| FY2019 | $2.4B | −10% |
| FY2018 | $2.7B | +18% |
| FY2017 | $2.3B | +3% |
| FY2016 | $2.2B | n/a |
| FY2015 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $320.1M | −17% | $1.4B | |
| Q1 FY26 | $320.6M | −12% | $1.4B | |
| Q4 FY25 | $370.3M | −17% | $1.5B | |
| Q3 FY25 | $364.2M | −15% | $1.6B | |
| Q2 FY25 | $386.1M | −12% | $1.6B | |
| Q1 FY25 | $364.5M | −13% | $1.7B | |
| Q4 FY24 | $445.6M | −9% | $1.7B | |
| Q3 FY24 | $430.1M | −14% | $1.8B | |
| Q2 FY24 | $439.1M | −12% | $1.8B | |
| Q1 FY24 | $417.3M | −13% | $1.9B | |
| Q4 FY23 | $488.6M | −6% | $2B | |
| Q3 FY23 | $498.8M | −7% | $2B |
Against its peers
Companies in Healthcare nearest NU Skin Enterprises' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| NUSNU Skin Enterprises | $1.4B | −15% a year |
| UTMDUtah Medical Products | $36.1M | −7% a year |
| ELMDElectromed | $73.8M | +15% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| PDEXPro DEX | $77.5M | +16% a year |
| INFUInfuSystem | $143.3M | +2% a year |
| VMDViemed Healthcare | $301.6M | +25% a year |
| EMBCEmbecta | $1B | −8% a year |
| ARVNArvinas | $316.7M | −15% a year |
| NRCNRC Health | $140M | −0% a year |
| Peer median | $141.7M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on NU Skin Enterprises
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.